NO802215L - Anti-psykotisk aktive ftalimidinderivater og fremgangsmaate til deres fremstilling - Google Patents

Anti-psykotisk aktive ftalimidinderivater og fremgangsmaate til deres fremstilling

Info

Publication number: NO802215L
Authority: NO; Norway
Prior art keywords: compound; carbon atoms; formula; hydrogen; halogen
Prior art date: 1979-08-27

Application number

NO802215A

Other languages

English (en)

Norwegian (no)

Inventor

Karl Stefan Bengtsson

Seth Olov Thorberg

Sven Ove Oegren

Original Assignee

Astra Laekemedel Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-08-27

Filing date

1980-07-23

Publication date

1981-03-02

1980-07-23 Application filed by Astra Laekemedel Ab filed Critical Astra Laekemedel Ab

1981-03-02 Publication of NO802215L publication Critical patent/NO802215L/no

Links

238000000034 method Methods 0.000 title claims description 36
238000002360 preparation method Methods 0.000 title claims description 32
230000000561 anti-psychotic effect Effects 0.000 title claims description 12
150000001875 compounds Chemical class 0.000 claims description 111
229910052739 hydrogen Inorganic materials 0.000 claims description 39
239000001257 hydrogen Substances 0.000 claims description 39
125000004432 carbon atom Chemical group C* 0.000 claims description 33
150000002431 hydrogen Chemical class 0.000 claims description 30
229910052736 halogen Inorganic materials 0.000 claims description 29
150000002367 halogens Chemical class 0.000 claims description 29
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 27
125000003545 alkoxy group Chemical group 0.000 claims description 19
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
125000000217 alkyl group Chemical group 0.000 claims description 17
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 15
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 14
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 14
229910052794 bromium Inorganic materials 0.000 claims description 14
239000000460 chlorine Substances 0.000 claims description 14
229910052801 chlorine Inorganic materials 0.000 claims description 14
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 12
150000003839 salts Chemical class 0.000 claims description 12
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
239000002253 acid Substances 0.000 claims description 9
239000000825 pharmaceutical preparation Substances 0.000 claims description 9
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
229910052731 fluorine Inorganic materials 0.000 claims description 5
239000011737 fluorine Substances 0.000 claims description 5
239000003085 diluting agent Substances 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 3
-1 p-toluenesulfonyloxy Chemical group 0.000 claims description 3
208000028017 Psychotic disease Diseases 0.000 claims description 2
125000003710 aryl alkyl group Chemical group 0.000 claims description 2
125000003118 aryl group Chemical group 0.000 claims description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
125000001309 chloro group Chemical group Cl* 0.000 claims description 2
150000002148 esters Chemical class 0.000 claims description 2
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 2
239000003937 drug carrier Substances 0.000 claims 1
238000002844 melting Methods 0.000 description 25
230000008018 melting Effects 0.000 description 25
239000000203 mixture Substances 0.000 description 24
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 23
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
229960003638 dopamine Drugs 0.000 description 16
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
102000005962 receptors Human genes 0.000 description 10
108020003175 receptors Proteins 0.000 description 10
239000000243 solution Substances 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
239000003826 tablet Substances 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
229960004046 apomorphine Drugs 0.000 description 8
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
239000000047 product Substances 0.000 description 7
238000003786 synthesis reaction Methods 0.000 description 7
YUBDLZGUSSWQSS-UHFFFAOYSA-N 1-benzylpiperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CC=CC=C1 YUBDLZGUSSWQSS-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
238000009835 boiling Methods 0.000 description 6
239000002775 capsule Substances 0.000 description 6
239000007903 gelatin capsule Substances 0.000 description 6
208000013403 hyperactivity Diseases 0.000 description 6
239000003960 organic solvent Substances 0.000 description 6
BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 5
108010010803 Gelatin Proteins 0.000 description 5
150000001412 amines Chemical class 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
239000008273 gelatin Substances 0.000 description 5
229920000159 gelatin Polymers 0.000 description 5
235000019322 gelatine Nutrition 0.000 description 5
235000011852 gelatine desserts Nutrition 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
229960004940 sulpiride Drugs 0.000 description 5
YDWGXSRUBMBOSJ-UHFFFAOYSA-N 4-bromo-2-(bromomethyl)benzoyl bromide Chemical compound BrCC1=CC(Br)=CC=C1C(Br)=O YDWGXSRUBMBOSJ-UHFFFAOYSA-N 0.000 description 4
XVMKZAAFVWXIII-UHFFFAOYSA-N 5-fluoro-2-benzofuran-1,3-dione Chemical compound FC1=CC=C2C(=O)OC(=O)C2=C1 XVMKZAAFVWXIII-UHFFFAOYSA-N 0.000 description 4
206010042008 Stereotypy Diseases 0.000 description 4
239000002585 base Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000010438 heat treatment Methods 0.000 description 4
PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical class C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
229920001592 potato starch Polymers 0.000 description 4
239000007787 solid Substances 0.000 description 4
BRUKSTGIAUDJQX-UHFFFAOYSA-N 1-[(4-methylphenyl)methyl]piperidin-4-amine Chemical compound C1=CC(C)=CC=C1CN1CCC(N)CC1 BRUKSTGIAUDJQX-UHFFFAOYSA-N 0.000 description 3
HVXXOIGTXJOVON-UHFFFAOYSA-N 6-formyl-2,3-dimethoxybenzoic acid Chemical compound COC1=CC=C(C=O)C(C(O)=O)=C1OC HVXXOIGTXJOVON-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
150000008064 anhydrides Chemical class 0.000 description 3
230000005540 biological transmission Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
238000005303 weighing Methods 0.000 description 3
WBSHFSDUPGHVSM-UHFFFAOYSA-N 2-(bromomethyl)-4-chlorobenzoyl bromide Chemical compound ClC1=CC=C(C(Br)=O)C(CBr)=C1 WBSHFSDUPGHVSM-UHFFFAOYSA-N 0.000 description 2
WNZQDUSMALZDQF-UHFFFAOYSA-N 2-benzofuran-1(3H)-one Chemical compound C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
JFRRHWPXPJGZLY-UHFFFAOYSA-N 4-bromo-2-methylbenzoyl chloride Chemical compound CC1=CC(Br)=CC=C1C(Cl)=O JFRRHWPXPJGZLY-UHFFFAOYSA-N 0.000 description 2
BTTRMCQEPDPCPA-UHFFFAOYSA-N 4-chlorophthalic anhydride Chemical compound ClC1=CC=C2C(=O)OC(=O)C2=C1 BTTRMCQEPDPCPA-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
230000004913 activation Effects 0.000 description 2
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
230000001055 chewing effect Effects 0.000 description 2
238000001816 cooling Methods 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000012458 free base Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
239000013067 intermediate product Substances 0.000 description 2
230000002197 limbic effect Effects 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
SGFACFBLUAWICV-UHFFFAOYSA-N methyl 4-bromo-2-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=C(Br)C=C1CBr SGFACFBLUAWICV-UHFFFAOYSA-N 0.000 description 2
150000002825 nitriles Chemical class 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000000376 reactant Substances 0.000 description 2
238000010992 reflux Methods 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
229940095064 tartrate Drugs 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
239000001993 wax Substances 0.000 description 2
SKYZYDSNJIOXRL-BTQNPOSSSA-N (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol;hydrochloride Chemical compound Cl.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 SKYZYDSNJIOXRL-BTQNPOSSSA-N 0.000 description 1
XGASTRVQNVVYIZ-UHFFFAOYSA-N 1-(chloromethyl)-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(CCl)=C1 XGASTRVQNVVYIZ-UHFFFAOYSA-N 0.000 description 1
BIMZLZOTBSPLRM-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]piperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CC=C(Cl)C=C1 BIMZLZOTBSPLRM-UHFFFAOYSA-N 0.000 description 1
ZCTWGHYTGOWQSN-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]piperidin-4-one Chemical compound C1=CC(Cl)=CC=C1CN1CCC(=O)CC1 ZCTWGHYTGOWQSN-UHFFFAOYSA-N 0.000 description 1
SJZKULRDWHPHGG-UHFFFAOYSA-N 1-benzylpiperidin-4-one Chemical class C1CC(=O)CCN1CC1=CC=CC=C1 SJZKULRDWHPHGG-UHFFFAOYSA-N 0.000 description 1
DDQYOKLLKGGMSH-UHFFFAOYSA-N 2,3-dihydroisoindol-1-one;hydrochloride Chemical compound Cl.C1=CC=C2C(=O)NCC2=C1 DDQYOKLLKGGMSH-UHFFFAOYSA-N 0.000 description 1
BKBQJEGATMJTIY-UHFFFAOYSA-N 2-(bromomethyl)benzoyl bromide Chemical compound BrCC1=CC=CC=C1C(Br)=O BKBQJEGATMJTIY-UHFFFAOYSA-N 0.000 description 1
FCBUKWWQSZQDDI-SESCQDRSSA-N 2-O-alpha-L-rhamnosyl-alpha-L-rhamnosyl-3-hydroxydecanoyl-3-hydroxydecanoic acid Chemical compound CCCCCCCC(CC(O)=O)OC(=O)CC(CCCCCCC)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 FCBUKWWQSZQDDI-SESCQDRSSA-N 0.000 description 1
LRJYRDODMNDLFR-UHFFFAOYSA-N 4,7-dimethoxy-2-benzofuran-1,3-dione Chemical compound COC1=CC=C(OC)C2=C1C(=O)OC2=O LRJYRDODMNDLFR-UHFFFAOYSA-N 0.000 description 1
DRYFDUUAYSVNSN-UHFFFAOYSA-N 4-(piperidin-1-ylmethyl)aniline Chemical compound C1=CC(N)=CC=C1CN1CCCCC1 DRYFDUUAYSVNSN-UHFFFAOYSA-N 0.000 description 1
WWJAZKZLSDRAIV-UHFFFAOYSA-N 4-fluoro-2-benzofuran-1,3-dione Chemical compound FC1=CC=CC2=C1C(=O)OC2=O WWJAZKZLSDRAIV-UHFFFAOYSA-N 0.000 description 1
125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 1
DVIKZIPMTWLDLT-UHFFFAOYSA-N 5,6-dibromo-2-benzofuran-1,3-dione Chemical compound C1=C(Br)C(Br)=CC2=C1C(=O)OC2=O DVIKZIPMTWLDLT-UHFFFAOYSA-N 0.000 description 1
WXCCTWHDROPVJN-UHFFFAOYSA-N 5-bromo-2-(bromomethyl)benzoyl bromide Chemical compound BrCC1=CC=C(Br)C=C1C(Br)=O WXCCTWHDROPVJN-UHFFFAOYSA-N 0.000 description 1
ZOXBWJMCXHTKNU-UHFFFAOYSA-N 5-methyl-2-benzofuran-1,3-dione Chemical compound CC1=CC=C2C(=O)OC(=O)C2=C1 ZOXBWJMCXHTKNU-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
229920000945 Amylopectin Polymers 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000009132 Catalepsy Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
206010024264 Lethargy Diseases 0.000 description 1
206010026749 Mania Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229920005439 Perspex® Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
241000009298 Trigla lyra Species 0.000 description 1
206010047853 Waxy flexibility Diseases 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000003354 anti-apomorphinic effect Effects 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
229960003990 apomorphine hydrochloride Drugs 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000012267 brine Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
150000003943 catecholamines Chemical class 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
WGXZDYPGLJYBJW-UHFFFAOYSA-N chloroform;propan-2-ol Chemical compound CC(C)O.ClC(Cl)Cl WGXZDYPGLJYBJW-UHFFFAOYSA-N 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
FBKCZNJUQYDVPL-UHFFFAOYSA-N cyclohexane;2-propan-2-yloxypropane Chemical compound C1CCCCC1.CC(C)OC(C)C FBKCZNJUQYDVPL-UHFFFAOYSA-N 0.000 description 1
239000007950 delayed release tablet Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000007938 effervescent tablet Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
101150006061 neur gene Proteins 0.000 description 1
230000000701 neuroleptic effect Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
210000001009 nucleus accumben Anatomy 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000005936 piperidyl group Chemical group 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
238000006268 reductive amination reaction Methods 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
238000000926 separation method Methods 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000000829 suppository Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
235000010215 titanium dioxide Nutrition 0.000 description 1
230000007306 turnover Effects 0.000 description 1
239000002966 varnish Substances 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychiatry (AREA)
Pharmacology & Pharmacy (AREA)
Neurosurgery (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)

NO802215A 1979-08-27 1980-07-23 Anti-psykotisk aktive ftalimidinderivater og fremgangsmaate til deres fremstilling NO802215L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE7907121A SE7907121L (sv)	1979-08-27	1979-08-27	Ftalimidinderivat

Publications (1)

Publication Number	Publication Date
NO802215L true NO802215L (no)	1981-03-02

Family

ID=20338703

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO802215A NO802215L (no)	1979-08-27	1980-07-23	Anti-psykotisk aktive ftalimidinderivater og fremgangsmaate til deres fremstilling

Country Status (12)

Country	Link
US (1)	US4289781A (es)
EP (1)	EP0026749A1 (es)
JP (1)	JPS5634679A (es)
AU (1)	AU6151380A (es)
DK (1)	DK365280A (es)
ES (6)	ES8106723A1 (es)
FI (1)	FI802686A7 (es)
IL (1)	IL60478A0 (es)
NO (1)	NO802215L (es)
SE (1)	SE7907121L (es)
SU (1)	SU969164A3 (es)
ZA (1)	ZA804057B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1169078A (en) *	1980-12-29	1984-06-12	Michael J. Fifolt	Method for the preparation of fluorophthalamic compounds
ZA83508B (en) *	1982-01-27	1983-10-26	Britax Wingard Ltd	Ferrule attachment
EP0093488A3 (en) *	1982-03-18	1984-05-23	Beecham Group Plc	Nortropyl benzopyrrolinone compounds, process for their preparation and pharmaceutical compositions containing them
US4600758A (en) *	1982-11-12	1986-07-15	Mead Johnson & Company	Isoindole derivatives
US4495194A (en) *	1982-11-12	1985-01-22	Mead Johnson & Company	Antihypertensive isoindole derivatives
US4505911A (en) *	1983-10-13	1985-03-19	Mead Johnson & Company	Isoindole diuretic derivatives, compositions and use
US4585773A (en) *	1984-07-11	1986-04-29	Bristol-Myers Company	Isoindolinyl-alkyl-piperazines
JPS6169773A (ja) *	1984-09-14	1986-04-10	Takeda Chem Ind Ltd	イソインドリノン誘導体
FI95572C (fi) *	1987-06-22	1996-02-26	Eisai Co Ltd	Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JPH0615934Y2 (ja) *	1987-11-13	1994-04-27	東レ・モノフィラメント株式会社	合成樹脂モノフィラメントの連結構造体
EP0351283A1 (fr) *	1988-07-12	1990-01-17	Synthelabo	Dérivés de [(pipéridinyl-4) méthyl]-2 dihydro-2,3 1H-isoindole et tétrahydro-2,3,4,5 1H-benzazépines, leur préparation et leur application en thérapeutique
US5210090A (en) *	1989-09-05	1993-05-11	G. D. Searle & Co.	Substituted N-benzylpiperidine amides and cardiac regulatory compositions thereof
US5053413A (en) *	1989-09-05	1991-10-01	G. D. Searle & Co.	N-benzylpiperidineisoindolinones
US5028616A (en) *	1989-09-05	1991-07-02	G. D. Searle & Co.	N-benzylpiperidine amides
US5070094A (en) *	1989-09-05	1991-12-03	G. D. Searle & Co.	N-benzyltropaneamides
US4992446A (en) *	1989-09-05	1991-02-12	G. D. Searle & Co.	Tricyclic quinolizine amides
US5098915A (en) *	1989-09-05	1992-03-24	G. D. Searle & Co.	Substituted N-benzylpiperidine amides
EP0497843A4 (en) *	1989-10-27	1992-09-23	The Du Pont Merck Pharmaceutical Company	(n-phthalimidoalkyl) piperidines
US5356906A (en) *	1989-10-27	1994-10-18	The Du Pont Merck Pharmaceutical Company	(N-phthalimidoalkyl) piperidines useful as treatments for psychosis
JP2807577B2 (ja) *	1990-06-15	1998-10-08	エーザイ株式会社	環状アミド誘導体
US5162341A (en) *	1991-02-22	1992-11-10	Du Pont Merck Pharmaceutical Company	Use of sigma receptor antagonists for treatment of amphetamine abuse
US5739135A (en) *	1993-09-03	1998-04-14	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
US5567718A (en) *	1994-08-11	1996-10-22	Hoechst Marion Roussel Inc.	2,3-dihydro-1h-isoindole derivatives and their use as serotonin reuptake inhibitors
US5885983A (en) *	1996-05-10	1999-03-23	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
US5827875A (en) *	1996-05-10	1998-10-27	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
US5883109A (en) *	1996-07-24	1999-03-16	Bristol-Myers Squibb Company	Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US5760246A (en)	1996-12-17	1998-06-02	Biller; Scott A.	Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
WO2000000472A1 (en) *	1998-06-30	2000-01-06	Du Pont Pharmaceuticals Company	5-ht7 receptor antagonists
FI20021421A0 (fi) *	2002-07-30	2002-07-30	Orion Corp Fermion	Valmistusmenetelmä
US6881815B2 (en) *	2002-09-25	2005-04-19	General Electric Company	Method for the preparation poly(etherimide)s
TW200918062A (en) *	2007-09-12	2009-05-01	Wyeth Corp	Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists
US8278302B2 (en) *	2009-04-08	2012-10-02	Boehringer Ingelheim International Gmbh	Substituted piperidines as CCR3 antagonists
UA109290C2 (uk)	2010-10-07	2015-08-10		Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es)	2012-04-02	2014-11-19	Boehringer Ingelheim Int	Proceso para la produccion de inhibidores de crr
US10213421B2 (en)	2012-04-04	2019-02-26	Alkahest, Inc.	Pharmaceutical formulations comprising CCR3 antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE333734B (es)	1969-04-23	1971-03-29	Kabi Ab
IL34317A0 (en)	1969-04-23	1970-06-17	Kabi Ab	Substituted acetamides,their preparation and pharmaceutical compositions containing them
GB1425578A (en) *	1972-10-21	1976-02-18	Wyeth John & Brother Ltd	Piperidine derivatives
GB1486104A (en)	1975-01-23	1977-09-21	Wyeth John & Brother Ltd	Phthalimidopiperidine derivatives
US4053615A (en) *	1972-10-21	1977-10-11	John Wyeth & Brother Limited	Phthalimidopiperidines and anti-convulsant compositions thereof
US4000287A (en) *	1974-12-16	1976-12-28	Ciba-Geigy Corporation	Isoindolinopiperidines

1979
- 1979-08-27 SE SE7907121A patent/SE7907121L/xx not_active Application Discontinuation
1980
- 1980-06-26 EP EP80850104A patent/EP0026749A1/en not_active Ceased
- 1980-07-03 IL IL60478A patent/IL60478A0/xx unknown
- 1980-07-04 ZA ZA00804057A patent/ZA804057B/xx unknown
- 1980-07-23 NO NO802215A patent/NO802215L/no unknown
- 1980-08-14 US US06/177,888 patent/US4289781A/en not_active Expired - Lifetime
- 1980-08-15 AU AU61513/80A patent/AU6151380A/en not_active Abandoned
- 1980-08-26 ES ES494508A patent/ES8106723A1/es not_active Expired
- 1980-08-26 DK DK365280A patent/DK365280A/da unknown
- 1980-08-26 ES ES494506A patent/ES494506A0/es active Granted
- 1980-08-26 FI FI802686A patent/FI802686A7/fi not_active Application Discontinuation
- 1980-08-26 ES ES494507A patent/ES8104275A1/es not_active Expired
- 1980-08-26 ES ES494502A patent/ES8103743A1/es not_active Expired
- 1980-08-26 SU SU802969263A patent/SU969164A3/ru active
- 1980-08-26 ES ES494505A patent/ES8106721A1/es not_active Expired
- 1980-08-26 ES ES494504A patent/ES494504A0/es active Granted
- 1980-08-27 JP JP11716580A patent/JPS5634679A/ja active Pending

Also Published As

Publication number	Publication date
ES494502A0 (es)	1981-03-16
ES8103744A1 (es)	1981-03-16
ES8103743A1 (es)	1981-03-16
SU969164A3 (ru)	1982-10-23
ES494507A0 (es)	1981-04-01
ES494508A0 (es)	1981-08-01
ES8106723A1 (es)	1981-08-01
IL60478A0 (en)	1980-09-16
ZA804057B (en)	1981-07-29
JPS5634679A (en)	1981-04-06
ES8104275A1 (es)	1981-04-01
SE7907121L (sv)	1981-02-28
ES494505A0 (es)	1981-08-01
EP0026749A1 (en)	1981-04-08
ES494504A0 (es)	1981-03-16
ES8106722A1 (es)	1981-08-01
AU6151380A (en)	1981-03-05
ES8106721A1 (es)	1981-08-01
FI802686A7 (fi)	1981-01-01
US4289781A (en)	1981-09-15
ES494506A0 (es)	1981-08-01
DK365280A (da)	1981-02-28

Publication	Publication Date	Title
NO802215L (no)	1981-03-02	Anti-psykotisk aktive ftalimidinderivater og fremgangsmaate til deres fremstilling
US8697876B2 (en)	2014-04-15	Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
US7737171B2 (en)	2010-06-15	Uses of 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIS
RU2116297C1 (ru)	1998-07-27	Производные 1,3-замещенного циклоалкена и циклоалкана в форме смеси изомеров или отдельных изомеров, или их гидраты, или соли
JPH064587B2 (ja)	1994-01-19	新規なインドール誘導体およびその酸付加塩ならびにそれらを含有する精神病治療剤
DE69105659T2 (de)	1995-04-27	3-Arylindol- und 3-Arylindazolderivate.
US20130231369A1 (en)	2013-09-05	1-[(4-hydroxypiperidin-4-yl)methyl]pyridin-2(1H)-one derivatives, preparation methods and uses thereof
NO20032636L (no)	2003-06-11	3-indolinderivater som er nyttige i behandlingen av psykiatriske og nevrologiske forstyrrelser
US6355642B1 (en)	2002-03-12	Tetrahydrobenzindole compounds
AU2009232836A1 (en)	2009-10-08	Indolinone compound
EA022776B1 (ru)	2016-02-29	Арилсульфонамиды для лечения заболеваний цнс
EA011635B1 (ru)	2009-04-28	Новые производные амида гетероциклической карбоновой кислоты
KR20120112726A (ko)	2012-10-11	５?ｈｔ６ 수용체 리간드인 술폰 화합물
PT99673B (pt)	1999-05-31	Processo para a preparacao de derivados de 1-piperazino-indano e de composicoes farmaceuticas que os contem
KR102438588B1 (ko)	2022-08-31	무스카린 m1 수용체 양성 알로스테릭 조절제로서 헤테로아릴 화합물
DE69529790T2 (de)	2003-11-06	Imidazolin-Derivate, deren Herstellung und deren Verwendung als Tachykinin-Rezeptor Antagonisten
US20060183902A1 (en)	2006-08-17	Dihydroindolyl methanones as alpha 1a/1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms
JPH08333362A (ja)	1996-12-17	新規インドール、インダゾール及びベンゾイソオキサゾール化合物、その製造方法ならびにそれを含む医薬組成物
JPS6351154B2 (es)	1988-10-13
JPS60158170A (ja)	1985-08-19	エテニルフェノールインドール誘導体及びそれらの塩、これらの製造方法並びにこれらを含有する薬剤
NO323236B1 (no)	2007-02-05	Indolderivater, deres anvendelse og farmasoytiske sammensetninger omfattende disse
US5089497A (en)	1992-02-18	Substituted piperazines as central nervous system agents
EA010893B1 (ru)	2008-12-30	Новые производные бензоилмочевины
CA2551168C (en)	2011-09-13	2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri
NO863924L (no)	1982-09-13	Mellomprodukter for bruk ved fremstilling av terapeutisk virksomme benzamidderivater.